- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Teva receives FDA approval for generic Lovaza
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
SILVER SPRING, Md. The Food and Drug Administration has approved a generic treatment made by Lupin Pharmaceuticals for allergies, according to FDA records.
The drug is a generic version of Schering-Plough’s Clarinex.
Clarinex has annual sales of around $229 million, according to IMS Health data reported by several media in India, where Lupin is based.